On December 17, 2020, the U.S. District Court for the District of Kansas granted summary judgment in favor of Compass Lexecon’s client Mylan Inc. on antitrust claims brought by Sanofi-Aventis U.S. LLC ("Sanofi"). Sanofi alleged that Mylan entered rebate agreements...

Court Relies on Testimony of Compass Lexecon Expert Professor Daniel R. Fischel On October 1, 2018, Vice Chancellor J. Travis Laster of the Delaware Court of Chancery, relying on Compass Lexecon President Daniel Fischel's expert testimony on behalf of Compass...

On August 28, 2017, the District Court in this case denied Plaintiffs’ motion to certify a class of direct purchasers of Cephalon’s branded drug Provigil. Direct purchaser Plaintiffs alleged that Cephalon delayed market entry of generic versions of Provigil through...

Compass Lexecon Expert Professor Bobby Willig Testifies Successfully for Defendants; Plaintiffs' Expert Excluded under Daubert In In re: Wellbutrin XL Antitrust Litigation, Compass Lexecon's clients, SmithKline Beecham Corporation d/b/a GlaxoSmithKline and GlaxoSmithKline plc (collectively, "GSK"), prevailed in a major pay-for-delay...

On January 9, 2012, the Superior Court of California (County of Santa Clara) granted a complete victory to Compass Lexecon’s client, DVD CCA. The Court ruled that Kaleidescape, a manufacturer of DVD movie servers, breached its license agreement with DVD...

In January 2011, the U.S. District Court (Southern District of Florida) granted summary judgment in favor of Compass Lexecon’s client, Nielsen, on Sunbeam’s antitrust claims. Sunbeam, operator of the FOX television affiliate in the Miami-Fort Lauderdale area, alleged that Nielsen,...

On March 29, 2010, Cisco Systems, Inc. received approval from the European Commission for its proposed acquisition of Tandberg ASA, the largest provider of videoconferencing equipment in the world. On that same day, the Department of Justice announced that it...

Direct purchasers, indirect purchasers, and generic manufacturers sued Abbott Laboratories and Fournier in these cases alleging that the introduction of new formulations (and subsequent delisting of the old formulations) of the cholesterol drug TriCor harmed competition by hindering generic manufacturers’...

Indirect purchasers of Schering-Plough’s potassium chloride drug, K-Dur, sued Schering-Plough Corporation, Upsher-Smith Laboratories, Inc., and Wyeth, alleging that patent settlement agreements between Schering-Plough and the generic manufacturers harmed consumers by delaying entry of generic versions of K-Dur. Dan Rubinfeld, supported...